about
Cancer prevention: state of the art and future prospectsPaving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the FateRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerMolecular mimics of the tumour antigen MUC1Mechanism and Function of Angiogenin in Prostate Cancer.Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First BiopsyGranulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.The role of chemotherapy and new targeted agents in the management of primary prostate cancer.Metabolic and toxicological considerations of newly approved prostate cancer drugs.Immune response to sipuleucel-T in prostate cancerSenescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer.The role of myeloid cells in cancer therapies.The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases.Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.Personalized medicine could transform healthcare.The role of gamma interferon in DNA vaccine-induced tumor immunity targeting simian virus 40 large tumor antigen.A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study.Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine modelPromising clinical application of ctDNA in evaluating immunotherapy efficacy
P2860
Q26770668-0BFA38FD-6EF3-443E-97AE-EE54211914A0Q26777205-381A1C69-834D-4BA1-9EF0-2F16B92F0B0AQ27028084-D8D72F05-0F71-47CC-ADA4-CFB4B1220024Q28485169-A892B519-0958-48A2-ABAA-882C537A112DQ36888285-F229667F-2633-49E9-8D5C-6C6C12777647Q37014809-2C078D34-1FB5-4CA0-A4BD-58B0CF6781D5Q37035678-FE50060B-FD35-4082-92DC-E059885890E8Q37708171-B20B4BE1-B5CE-4139-A58D-333684B63271Q38098596-B7E880C2-6336-4AF9-BFC8-AB94F9ACE6B0Q38161390-DD0F8D6F-BD03-401D-A8F6-51611AE86F46Q38207592-86D5FFC4-1AFB-4895-AF9B-FE2F3F19A202Q38875474-A8FF0592-C07E-476D-A5A6-6312216B0A55Q39145269-47CD0C3E-C24F-4C35-9F6A-C0C8BEFE1674Q39210287-FBCC1ED1-B61F-4410-A434-78960EAC075EQ39412983-0202691A-F3AD-4C4E-950B-D46F041E8FE3Q39415827-B8F90DF3-5DC7-4A53-A202-7F5E89481BDDQ40991086-F63F33AF-ECCE-45CC-B028-A42FD443D4ADQ45355231-9490E6C8-4FE9-4B01-AD97-4858DEC63B33Q47953839-BE9C96EB-B882-47D1-817C-8D5BEE00DE04Q54945681-6C4B38BE-8441-40FD-8E60-D359E63B7856Q58779761-C8BCE7A2-7DCD-4256-B50C-FF6B6485249FQ58790057-D4FD8FA9-81DB-4099-9213-56BBAE06F935
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cancer immunotherapy: sipuleucel-T and beyond.
@ast
Cancer immunotherapy: sipuleucel-T and beyond.
@en
Cancer immunotherapy: sipuleucel-T and beyond.
@nl
type
label
Cancer immunotherapy: sipuleucel-T and beyond.
@ast
Cancer immunotherapy: sipuleucel-T and beyond.
@en
Cancer immunotherapy: sipuleucel-T and beyond.
@nl
prefLabel
Cancer immunotherapy: sipuleucel-T and beyond.
@ast
Cancer immunotherapy: sipuleucel-T and beyond.
@en
Cancer immunotherapy: sipuleucel-T and beyond.
@nl
P2093
P2860
P356
P1433
P1476
Cancer immunotherapy: sipuleucel-T and beyond.
@en
P2093
Aimee E Hammerstrom
Bradley J Atkinson
Diana H Cauley
Padmanee Sharma
P2860
P304
P356
10.1592/PHCO.31.8.813
P407
P577
2011-08-01T00:00:00Z